Search

everythinglearnresearchcommunity

for

Search:↓

The Swedish neonatal screening program effectively detects PKU, galactosaemia, and biotinidase deficiency with low false positives.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Levothyroxine effectively treated a dog's skin and hair problems caused by hypothyroidism.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

An over-the-counter vitamin/mineral supplement improved hair loss and blood sugar control in a woman with non-classic 11-hydroxylase deficiency.

A woman with hypothyroidism developed an allergy to IV levothyroxine after being resistant to oral forms.

Newer GLP-1 drugs like semaglutide may cause hair loss.

Tofacitinib helped regrow hair in a lupus patient with alopecia.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

Voglibose may help treat skin hyperpigmentation safely.

TCF/Lef1 is essential for skin barrier function by regulating lipid metabolism.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Feeding steers only Leucaena leucocephala causes severe health issues and poor weight gain.

Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.

GLP-1 receptor agonists may cause hair loss, but more research is needed.

A woman survived a massive lithium overdose that caused a form of hair loss.

Naltrexone shows promise as a safe treatment for a type of hair loss called lichen planopilaris.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

A nutrition program significantly improved a woman's lupus symptoms.

Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.